Peptide-related content has passed 130,000 posts on Instagram and 230 million views on TikTok, and a Viewpoint published June 15 in JAMA ↗ argues that regulation has not kept pace. The authors, from the University of Queensland, the University of Toronto, and the University of California, San Francisco, call the consumer market for injectable peptides a regulatory gray zone that spans medicine, wellness, and the illicit drug trade, and they say the safety research needed to govern it does not yet exist.
The substances they are describing are not the weight-loss drugs most people now associate with the word peptide. They are compounds like BPC-157 ↗, a fragment marketed for healing tendons and gut tissue, TB-500 ↗, a synthetic version of a repair protein, and CJC-1295 ↗, a long-acting trigger for growth hormone release. People buy them online and inject them for muscle growth, faster recovery from injury, anti-aging, and sharper focus. None is an FDA-approved drug. Most of the human evidence is thin, and much of what exists is in animals.
Why "gray zone" is the right phrase
A normal drug is either approved or it is not, and an unapproved one is illegal to sell for treatment. These peptides sit in between. They are sold as research chemicals, as supplements, or through compounding pharmacies that mix drugs to order. Each channel has its own rules and its own gaps. A buyer can get a vial without a prescription. There is no guarantee that the contents match the label or that the dose is safe. The JAMA authors point to that mismatch between how easy these compounds are to get and how little is known about them as the core problem.
The numbers they cite are about attention, not patients. Worldwide Google searches for peptides have climbed roughly sixfold since 2024, from about 1.3 million a month to around 8 million. That is demand running well ahead of evidence, and the authors argue the honest response is to fund safety studies and write clearer rules rather than wait for harm reports to accumulate.
The supply side moves next month
The demand side that JAMA describes is about to meet a supply-side decision. The FDA has scheduled its Pharmacy Compounding Advisory Committee for July 23 and 24 ↗. The panel will weigh seven of these same compounds for legal compounding under the 503A rule. That rule governs what a pharmacy may mix for an individual patient. The seven are BPC-157, TB-500, the tripeptide KPV, the mitochondrial peptide MOTS-c ↗, the sleep peptide DSIP, the longevity compound Epitalon ↗, and the Russian nootropic Semax ↗. A favorable vote would not approve any of them as a drug. It would only decide whether a pharmacy can compound them. That is a narrower question, and an easy one to confuse with approval. We walked through that distinction in April ↗, when the agency cleared twelve peptides off a restricted list and scheduled these seven for the panel.
What the evidence actually says
This is where a sequence-defined catalog has something to add that a search bar does not. Each of these compounds has a card on peptidemodel anchored to its exact sequence and its evidence tier, and the pattern across them is consistent. The mechanisms are often real and specific. BPC-157 has plausible tissue-repair biology, MOTS-c has genuine mitochondrial signaling, Semax has a documented effect on brain-derived neurotrophic factor. The controlled human trials that would turn any of that into a dosing recommendation are mostly missing. A reader who clicks through the social-media hype lands on the same gap the JAMA authors are pointing at.
The Viewpoint does not call for a ban. It calls for the studies that would let regulators say something specific instead of nothing. Six weeks before the FDA panel, that is the more useful demand. A rule written without the safety data is just a guess with a deadline.